Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant
therapy. The International Initiative on Thrombosis and Cancer is an...
An externally validated clinical prediction model incorporating only one clinical
factor (tumour-site category) and one biomarker (D-dimer) predicted the risk of venous
thromboembolism in ambulatory patients with solid cancers. This simple model is...
In contrast to venous thromboembolism, little is known about arterial thromboembolism in patients with cancer. The aim of this study was to quantify the risk and explore clinical risk factors of arterial thromboembolism in patients with cancer, and...
Cihan AyIn contrast to #VTE, little is known about #arterial thromboembolism in patients with #cancer. Frequency, risk factors and impact on mortality of arterial thromboembolism in patients with cancer are reported in this paper in @haematologica. @EHA_Hematology